

Weekly Wrap of STI

The STI ended 0.26% or 8.17 points higher on Friday to close at 3117.61 to cap off a broadly upbeat week as the market looks to a much awaited G-20 meeting between US President Donald Trump and his Chinese counterpart Xi Jinping on Saturday for a thaw in US-China tensions.

At the start of the week, the STI rose over the surprising rebound of Singapore's October manufacturing data and strong sales figures from Cyber Monday, which was set to exceed the US\$6.6 billion quantum last year. However, momentum was halted as fresh threats from US president Donald Trump to widen the scope of tariffs on Chinese imports surfaced. The market was given an uplift following US Federal Reserve chair Jerome Powell's dovish speech about a more gradual interest rise hike. The STI ended the week on a largely upbeat note, but kept gains modest as fears of escalating US-China trade tensions weighed ultimately on the investors' minds.

Year to date, the STI index is down by 8.4% while the Catalist index is down by 31.6%.

Week Ahead: 03 December – 07 December 2018

Economic Calendar: China PMI Manufacturing Index (03 Dec), UK PMI Manufacturing Index (03 Dec), US ISM Manufacturing Index (03 Dec), China General Services PMI (05 Dec), UK PMI Services Index (05 Dec), Euro PMI Composite (05 Dec), Euro Retail Sales (05 Dec), US PMI Services Index (05 Dec), US MBA Mortgage Applications (05 Dec), US EIA Petroleum Status Report (05 Dec), US International Trade (06 Dec), US Jobless Claims (06 Dec), Global Composite & Services PMI (06 Dec), US Employment Situation (07 Dec), US Wholesale Trade (07 Dec)

Company Results: -

Companies News

1. Advancer Global acquired landscaping company

Advancer Global Facility Pte. Ltd. ("**AGF**"), a wholly-owned subsidiary of Catalist-listed Advancer Global Limited ("**Advancer Global**"), together with Fat Trees Pte. Ltd. ("**Fat Trees**") had jointly acquired Country Cousins Pte. Ltd. ("**Country Cousins**"). Out of the total consideration of S\$225,000 for 100% of the total issued and paid-up share capital of Country Cousins, AGF will pay S\$171,000 and will hold 76% of Country Cousins while the balance 24% will be held by Fat Trees. The acquisition of landscaping and related services company Country Cousins will facilitate Advancer Global's entry into aquascapes and ponds and complement strategically the Group's services in outdoor living spaces.

2. Kim Heng to dispose assets for S\$12.5 million

Catalist-listed Kim Heng Offshore & Marine Holdings Limited ("**Kim Heng**"), through its wholly-owned subsidiary Kim Heng Heavy Equipment Pte. Ltd. ("**KHHE**") entered into a sale and purchase agreement with Hup Hin Heavy Equipment Pte. Ltd. ("**Hup Hin**") for the proposed sale of 24 cranes and 2 luffing jibs for S\$12.5 million. The proposed disposal is part of the Kim Heng's strategy to streamline and focus on the core business segments and to fund working capital needs, expand its business and pay down bank loans.

3. Acromec reported significantly lower loss for its FY2018 results

Catalist-listed Acromec Limited ("**Acromec**") reported a significantly lower loss in its results in FY2018, despite absorbing a massive one-off impact from the problems faced on its pharmaceutical plant project. The net loss attributable to shareholders of approximately S\$2.62 million for FY2018, a significant improvement of 43% as compared FY2017. Revenue remained relatively stable, buoyed by healthy level of business activities, with a small dip of 3%. Gross profit margins grew from 3% to 7% for FY2018.

4. Asian Healthcare Specialists recorded S\$2.5 million net profit in FY2018

Catalist-listed medical services group Asian Healthcare Specialists Limited ("**Asian Healthcare Specialists**") saw net profit surge 459.8% to S\$2.5 million for FY2018. Excluding one-off listing expenses not capitalised, the adjusted net profit would have been S\$3.4 million. Full-year revenue was S\$10.9 million, down a marginal 1.4% from S\$11 million the year before, which was attributed to fewer patient visits. The largest change in full-year expenses came from purchased and contracted services, which fell 97.6% to S\$171,000 due to the termination of consultancy services agreements and the commencement of employment agreements with four doctors. It also announced the acquisition of an anesthesia arm and a physiotherapy practice to expand its services.


5. Amplefield back in black for FY2018

Catalist-listed property developer and construction services provider Amplefield Limited ("**Amplefield**") posted a revenue of S\$11.2 million for FY2018 as compared to S\$1.3 million in the previous year. The huge increase was mainly attributed to the billings of S9.2 million from construction activities in Vietnam. Higher occupancy rate in its investment properties in the Philippines also contributed to the higher rental income at S\$2.0 million. In line with the construction activities in Vietnam, costs rose to S\$8.3 million. Overall, Amplefield posted a net profit of S\$620,000 for FY 2018, reversing the loss of S\$612,000 in the prior year.

Market Snapshot

Symbol	Price	Change	1D % Change	5D % Change	YTD % Change
STI	3117.6	▲ 8.2	▲ 0.3%	▲ 2.1%	▼ 8.4%
SG Mid Cap	698.0	▲ 1.4	▲ 0.2%	▲ 1.6%	▼ 9.0%
SG Catalist	321.6	▲ 0.5	▲ 0.1%	▼ 0.5%	▼ 31.6%
SG Small Cap	334.6	▲ 1.7	▲ 0.5%	▲ 2.1%	▼ 17.7%

Price Chart



IPO News

Biolidics lodges prospectus for Catalist IPO

Medical technology company Biolidics Limited ("**Biolidics**") is seeking to list on the Catalist board of the Singapore Exchange. Formerly known as Clearbridge Biomedics, the cancer diagnostic solutions developer is an associated company of Catalist-listed Clearbridge Health. It specialises in developing cell enrichment systems that can be combined with other analytical tests for cancer diagnosis, prognosis, treatment selection and treatment monitoring. Its main product is the ClearCell FX1 System, a fully automated in vitro diagnostic medical device which had been installed in academic and research institutes, hospitals and laboratories in Singapore, China, Hong Kong, Japan, the US and some European Union countries. Biolidics plans to use the IPO proceeds to develop the clinical applications and clinical services customer segment for its products and to expand its product pipeline. Biolidics reported a net loss of S\$2.8 million in 1H18, down from S\$4.2 million a year ago.

Medinex to price IPO at S\$0.25 per share.

Ahead of its listing on the Catalist board of the Singapore exchange, professional medical support services provider Medinex has priced its initial public offering ("**IPO**") at S\$0.25 a share. The IPO will raise gross proceeds of S\$7.5 million. Medinex will receive a net proceeds of S\$5.32 million. Based on the IPO price, Medinex will have a market cap of S\$32.8 million, which is 25 times its net profit of S\$1.3 million in 2017. The IPO comprises of a placement tranche of 30 million shares, comprising 26 million new shares and four million vendor shares. There is no public tranche and the placement closes on 5 December; trading will commence at 9am on 7 December. Medinex's sponsor and issue manager is Novus Corporate Finance. UOB Kay Hian is the placement agent.